Back to results
US 12,006,553 B2Granted
Companion diagnostics for mitochondrial inhibitors
AssigneeLunella Biotech, Inc.
InventorsMichael P. Lisanti, Federica Sotgia
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of identifying patients that may be responsive to mitochondrial inhibitor therapies to target and eradicate cancer stem cells. Also described are diagnostic kits that may be used to identify patients responsive to mitochondrial inhibitor therapies.
Claims9
A method for treating breast cancer in a breast cancer patient having mRNA levels of at least one of HSPD1, UQCRB, MRPL15, and COX17 mitochondrial markers exceeding a threshold level for the mitochondrial marker, the method comprising:
- obtaining a breast tumor sample obtained from a breast cancer patient having measured mRNA levels of at least one of HSPD1, UQCRB, MRPL15, and COX17 mitochondrial markers exceeding a threshold level for the mitochondrial marker;
- measuring an mRNA level of each of a plurality of mitochondrial markers in the breast tumor sample, the plurality comprising HSPD1, UQCRB, MRPL15, and COX17;
- and
- administering to the breast cancer patient having measured mRNA levels of at least one of the HSPD1, UQCRB, MRPL15, and COX17 mitochondrial markers exceeding a threshold level for the mitochondrial marker, a pharmaceutically effective amount of a mitochondrial inhibitor, the mitochondrial inhibitor selected from the group consisting of a mitoriboscin, a mitoketoscin, an antimitoscin, metformin, a tetracycline family member, an erythromycin family member, atovaquone, bedaquiline, and vitamin c.
1 more element
Dependencies are inferred from the claim text.